VitriVax Raises $17.25M Series B Led by Adjuvant Capital and RA Capital

Deal Summary

VitriVax, a vaccine formulation technology company, raised $17.25M in a Series B financing co-led by Adjuvant Capital and RA Capital Management to fund development and commercialization of its ALTA technology. The round aims to support continued advancement of thermostable antigen and adjuvant offerings.